Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Oct 2007

Marsh Sharon, Paul Jim, King Cristi R, Gifford Gillian, McLeod Howard L, Brown Robert

Abstract excerpt

PURPOSE: Standard therapy for advanced ovarian cancer consists of a platinum agent in combination with a taxane, which has a 5-year survival rate of approximately 45%. The large individual variability for ovarian cancer patients in both outcome and toxicity risk from chemotherapy makes the identification of pharmacogenetic markers that can be used to screen patients before therapy selection an attractive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Cisplatin

Share to Multidrug Resistance-Associated Protein 2

Share to Ovarian Neoplasms

Share to Paclitaxel

Share to Pharmacogenetics

Source

Identifiers

PMID: 17925548
DOI: 10.1200/JCO.2006.10.4752

Genes

ABCC2
ABCG2
ABCB1
ABCC1
ERCC1
ERCC2
GSTP1
MAPT
MPO
XRCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.PMID 17925548Read ↗

Pharmacogenomics of taxane/platinum therapy in ovarian cancer.Semantic proximity Read ↗

Genetic markers for prediction of treatment outcomes in ovarian cancer.Semantic proximity Read ↗

Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.Semantic proximity Read ↗

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.Semantic proximity Read ↗

‘Genetic profiling’ and ovarian cancer therapy (Review)Semantic proximity Read ↗

Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.Semantic proximity Read ↗

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsSemantic proximity Read ↗

Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.Semantic proximity Read ↗

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Semantic proximity Read ↗

Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.Semantic proximity Read ↗

Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity.Semantic proximity Read ↗

Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.